CannaPharmaRx Reports Revenue Growth but Faces Significant Financial Challenges in Q2 2026

CannaPharmaRx, Inc. reported its financial results for the second quarter of 2026, revealing a revenue increase to $276,218, up from $231,608 in the same period last year. For the first half of 2026, the company generated $903,680 in revenue, compared to $566,927 in the first half of 2025. Despite this growth in revenue, the company continues to face significant financial challenges, including a net loss of $1,909,042 for the quarter and $2,291,063 for the six-month period, reflecting losses of $1,413,458 and $2,104,052, respectively, in the prior year.

The company's cost of goods sold (COGS) decreased to $414,664 for the second quarter of 2026, down from $852,818 in the same quarter of 2025. This reduction was attributed to lower inventory impairment charges, which helped to mitigate the impact of increased sales volumes. The gross loss for the quarter was $138,446, a significant improvement from the $621,210 loss reported in the prior year. Operating expenses also rose to $240,385 from $219,770, primarily due to increased royalty expenses and professional fees.

CannaPharmaRx's balance sheet as of June 30, 2026, showed total assets of $6,891,942, a slight decrease from $7,018,404 at the end of 2025. Current liabilities increased to $32,569,584, compared to $31,589,958 at the end of the previous year, contributing to a working capital deficiency of $31,236,572. The company reported an accumulated deficit of $114,606,653, up from $112,315,590 at the end of 2025. The cash position also deteriorated, with only $555 available at the end of the quarter, down from $1,804 at the end of 2025.

Strategically, CannaPharmaRx is focused on expanding its cannabis cultivation operations in Canada, with plans to increase capacity at its facility in Alberta. The company has entered into a security and royalty agreement with Koze Investments LLC, which has become a related party due to management changes. As part of this agreement, the company is required to pay a royalty on cannabis product sales, which has led to increased royalty expenses. The company is also exploring opportunities to expand its sales network in European markets, particularly in Germany and Israel.

Looking ahead, CannaPharmaRx faces substantial doubt regarding its ability to continue as a going concern, primarily due to its liquidity challenges and reliance on related party financing. Management plans to address these issues through potential equity financing and debt arrangements. However, there is no assurance that these efforts will be successful, and the company may need to significantly reduce or cease operations if adequate financing is not secured.